|
93 Companies |
|
105 Products |
|
105 Products |
|
79 Mechanisms of Action |
|
1 Trial |
|
460 News |
|
| 12345678910» |
- | Enrollment change, Trial withdrawal, HEOR: Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 (clinicaltrials.gov) - Aug 21, 2024
P=N/A, N=0, Withdrawn, Sponsor: Gynecologic Oncology Group
N=2605 --> 0 | Not yet recruiting --> Withdrawn
- ||| TroVax (MVA 5T4) / Oxford Biomedica
Trial completion: TRIOC: The Activity of TroVax (clinicaltrials.gov) - May 9, 2019
P2, N=94, Completed, Sponsor: University College, London
N=2605 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy (clinicaltrials.gov) - Mar 21, 2019
P=N/A, N=107, Completed, Sponsor: University of Michigan
Active, not recruiting --> Completed Recruiting --> Completed | N=180 --> 107 | Trial completion date: Feb 2020 --> Oct 2017 | Trial primary completion date: Feb 2020 --> Oct 2017
- | Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, IMNN-001 / Imunon
Trial completion: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Mar 12, 2019
P1, N=16, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed | N=180 --> 107 | Trial completion date: Feb 2020 --> Oct 2017 | Trial primary completion date: Feb 2020 --> Oct 2017 Active, not recruiting --> Completed
- ||||||| Trial completion, Monotherapy: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Feb 6, 2019
P3, N=581, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- veliparib (ABT-888) / AbbVie
Enrollment closed, BRCA Biomarker, PARP Biomarker: Phase II ABT-888 With Cyclophosphamide (clinicaltrials.gov) - Jan 3, 2019
P2, N=29, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, veliparib (ABT-888) / AbbVie
Trial completion, Enrollment change, Trial primary completion date, PARP Biomarker: Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 3, 2019
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=58 --> 45 | Trial primary completion date: Oct 2016 --> May 2017
- | veliparib (ABT-888) / AbbVie
Trial completion, BRCA Biomarker, PARP Biomarker: Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy (clinicaltrials.gov) - Jan 3, 2019
P1, N=98, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=58 --> 45 | Trial primary completion date: Oct 2016 --> May 2017 Active, not recruiting --> Completed
- | Enrollment change, Trial withdrawal: Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer (clinicaltrials.gov) - Nov 28, 2018
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Active, not recruiting --> Completed N=20 --> 0 | Not yet recruiting --> Withdrawn
- | Trial completion, Trial completion date, Trial primary completion date: Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive (clinicaltrials.gov) - Nov 7, 2018
P=N/A, N=154, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
N=20 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Oct 2018 | Trial primary completion date: Dec 2019 --> Oct 2018
- ||| Avastin (bevacizumab) / Roche
Trial completion, Enrollment change: BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - Oct 16, 2018
P2, N=32, Completed, Sponsor: AA Secord
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Oct 2018 | Trial primary completion date: Dec 2019 --> Oct 2018 Active, not recruiting --> Completed | N=56 --> 32
- | Trial withdrawal, Metastases: ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment (clinicaltrials.gov) - Sep 18, 2018
P2, N=0, Withdrawn, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed | N=56 --> 32 Active, not recruiting --> Withdrawn
- | Mifeprex (mifepristone) / Danco Laboratories
Trial completion: Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Sep 11, 2018
P1, N=31, Completed, Sponsor: University of Chicago
Active, not recruiting --> Withdrawn Active, not recruiting --> Completed
- | Recentin (cediranib) / AstraZeneca
Trial completion, Metastases: Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer (clinicaltrials.gov) - Aug 29, 2018
P2, N=74, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
Trial completion, Combination therapy: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer (clinicaltrials.gov) - Jul 2, 2018
P2, N=63, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Phase classification, Enrollment change, Trial withdrawal, Trial primary completion date: PET Imaging of Ovarian Carcinoma With 18F-FSPG (clinicaltrials.gov) - Jun 6, 2018
P1, N=0, Withdrawn, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Phase classification: P=N/A --> P1 | N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Aug 2019
- | Trial termination: YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=2500, Terminated, Sponsor: Gynecologic Oncology Group
Phase classification: P=N/A --> P1 | N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Aug 2019 Active, not recruiting --> Terminated
- | Biomarker, Trial completion, Trial primary completion date: Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=39, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Terminated Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jan 2018
- | Trial completion: Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer (clinicaltrials.gov) - Jun 1, 2018
P2, N=100, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jan 2018 Recruiting --> Completed
- | MIS416 / Amplia Therap
Enrollment change, Trial withdrawal: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - May 1, 2018
P1, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed N=12 --> 0 | Recruiting --> Withdrawn
- | p53MVA - Tara I / O
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Apr 30, 2018
P1, N=12, Completed, Sponsor: City of Hope Medical Center
N=12 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Apr 2018 | Trial primary completion date: Aug 2018 --> Apr 2018
- | Sancuso (granisetron) / Cumberland
Trial termination: Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer (clinicaltrials.gov) - Apr 12, 2018
P=N/A, N=4, Terminated, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Apr 2018 | Trial primary completion date: Aug 2018 --> Apr 2018 Suspended --> Terminated; Study terminated due to no patient population available
- | Trial completion: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy (clinicaltrials.gov) - Apr 12, 2018
P=N/A, N=247, Completed, Sponsor: Gynecologic Oncology Group
Suspended --> Terminated; Study terminated due to no patient population available Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy (clinicaltrials.gov) - Mar 20, 2018
P=N/A, N=180, Recruiting, Sponsor: University of Michigan
Active, not recruiting --> Completed Trial completion date: Feb 2018 --> Feb 2020 | Trial primary completion date: Feb 2018 --> Feb 2020
- ||| Trial completion date, Monotherapy: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Mar 3, 2018
P3, N=586, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Feb 2018 --> Feb 2020 | Trial primary completion date: Feb 2018 --> Feb 2020 Trial completion date: Jan 2018 --> Dec 2018
- | Trial completion, Trial completion date, Trial initiation date, Trial primary completion date, HEOR, Surgery, Patient reported outcomes: Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life (clinicaltrials.gov) - Feb 15, 2018
P=N/A, N=120, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Jan 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Feb 2018 | Initiation date: Mar 2009 --> Mar 2009 | Trial primary completion date: Mar 2018 --> Feb 2018
- | Folotyn (pralatrexate) / Aurobindo
Trial completion, Phase classification, Trial primary completion date: Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 19, 2018
P1/2, N=50, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Feb 2018 | Initiation date: Mar 2009 --> Mar 2009 | Trial primary completion date: Mar 2018 --> Feb 2018 Active, not recruiting --> Completed | Phase classification: P2 --> P1/2 | Trial primary completion date: Jan 2018 --> Jul 2016
- ||||| Enrollment closed, Trial primary completion date, Monotherapy: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jan 16, 2018
P3, N=582, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | Phase classification: P2 --> P1/2 | Trial primary completion date: Jan 2018 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2018 --> Jan 2018
- | motesanib (AMG 706) / Takeda
Trial termination: AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 11, 2018
P2, N=23, Terminated, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2018 --> Jan 2018 Completed --> Terminated; Study was stopped for severe toxicity causing concern for patients
- | topotecan / Generic mfg., acetylcysteine solution / Generic mfg.
Biomarker, Trial termination, Trial primary completion date: Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jan 3, 2018
P2, N=1, Terminated, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Completed --> Terminated; Study was stopped for severe toxicity causing concern for patients Active, not recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Jun 2016; The trial was halted prematurely due to slow accrual.
- lenalidomide / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 28, 2017
P1/2, N=15, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Jun 2016; The trial was halted prematurely due to slow accrual. N=51 --> 15 | Suspended --> Terminated | Trial primary completion date: Jun 2013 --> Aug 2011; lack of funding
- | MIS416 / Amplia Therap
Enrollment open: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 28, 2017
P1, N=12, Recruiting, Sponsor: Roswell Park Cancer Institute
N=51 --> 15 | Suspended --> Terminated | Trial primary completion date: Jun 2013 --> Aug 2011; lack of funding Not yet recruiting --> Recruiting
- ||| TroVax (MVA 5T4) / Oxford Biomedica
Enrollment closed: TRIOC: The Activity of TroVax (clinicaltrials.gov) - Dec 15, 2017
P2, N=97, Active, not recruiting, Sponsor: University College, London
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Mifeprex (mifepristone) / Danco Laboratories
Trial primary completion date: Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 7, 2017
P1, N=31, Active, not recruiting, Sponsor: University of Chicago
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2017 --> Jun 2018
- | Enrollment change, Trial primary completion date, HEOR: A Survivorship Care Plan for Gynaecological Cancer Patients (clinicaltrials.gov) - Nov 24, 2017
P=N/A, N=150, Completed, Sponsor: Royal Marsden NHS Foundation Trust
Trial primary completion date: Nov 2017 --> Jun 2018 N=75 --> 150 | Trial primary completion date: Aug 2013 --> Mar 2014
- | veliparib (ABT-888) / AbbVie
Trial completion, Trial primary completion date, PARP Biomarker: Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer (clinicaltrials.gov) - Nov 21, 2017
P1, N=34, Completed, Sponsor: National Cancer Institute (NCI)
N=75 --> 150 | Trial primary completion date: Aug 2013 --> Mar 2014 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Nov 2016
- ||| TroVax (MVA 5T4) / Oxford Biomedica
Enrollment change, Trial primary completion date: TRIOC: The Activity of TroVax (clinicaltrials.gov) - Nov 1, 2017
P2, N=97, Recruiting, Sponsor: University College, London
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Nov 2016 N=75 --> 97 | Trial primary completion date: May 2017 --> May 2019
- ||| Avastin (bevacizumab) / Roche
Enrollment closed: BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - Oct 30, 2017
P2, N=56, Active, not recruiting, Sponsor: AA Secord
N=75 --> 97 | Trial primary completion date: May 2017 --> May 2019 Recruiting --> Active, not recruiting
- | veliparib (ABT-888) / AbbVie
Trial primary completion date, BRCA Biomarker, PARP Biomarker: Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy (clinicaltrials.gov) - Oct 16, 2017
P1, N=98, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> May 2011
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer (clinicaltrials.gov) - Oct 2, 2017
P2, N=63, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jun 2016 --> May 2011 Trial primary completion date: Mar 2017 --> Mar 2018
- | Avastin (bevacizumab) / Roche
Enrollment change, Trial termination: (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma (clinicaltrials.gov) - Sep 27, 2017
P2, N=7, Terminated, Sponsor: Western Regional Medical Center
Trial primary completion date: Mar 2017 --> Mar 2018 N=88 --> 7 | Recruiting --> Terminated; PI Decision
- | polyvalent vaccine-KLH conjugate / MabVax, Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Combination therapy, IO biomarker: Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab (clinicaltrials.gov) - Sep 13, 2017
P=N/A, N=22, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
N=88 --> 7 | Recruiting --> Terminated; PI Decision Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Sep 2017
- | polyvalent vaccine-KLH conjugate / MabVax
Trial completion, Trial primary completion date: OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission (clinicaltrials.gov) - Sep 6, 2017
P2, N=171, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Sep 2017 Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Sep 2015
- | Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, IMNN-001 / Imunon
Trial primary completion date: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 24, 2017
P1, N=16, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Sep 2015 Trial primary completion date: Dec 2014 --> Jul 2015
- epacadostat (INCB024360) / Incyte
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 24, 2017
P1, N=2, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Dec 2014 --> Jul 2015 Suspended --> Completed | N=20 --> 2 | Initiation date: Apr 2014 --> Jul 2014 | Trial primary completion date: Aug 2017 --> Nov 2015
- | topotecan / Generic mfg., acetylcysteine solution / Generic mfg.
Biomarker, Trial primary completion date: Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Aug 24, 2017
P2, N=1, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Suspended --> Completed | N=20 --> 2 | Initiation date: Apr 2014 --> Jul 2014 | Trial primary completion date: Aug 2017 --> Nov 2015 Trial primary completion date: Oct 2019 --> Jun 2017
- | p53MVA - Tara I / O
Trial primary completion date, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Aug 22, 2017
P1, N=9, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Oct 2019 --> Jun 2017 Trial primary completion date: Sep 2017 --> Aug 2018
- polyvalent vaccine-KLH conjugate / MabVax, Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, IO biomarker: Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab (clinicaltrials.gov) - Aug 18, 2017
P=N/A, N=22, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Sep 2017 --> Aug 2018 Trial primary completion date: Oct 2017 --> Oct 2018
- | Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, IMNN-001 / Imunon
Trial primary completion date: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 3, 2017
P1, N=18, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Oct 2017 --> Oct 2018 Trial primary completion date: Oct 2014 --> Dec 2014
- | Trial completion, Trial primary completion date: Detection of Chlamydia DNA by Polymerase Chain Reaction in Primary Tubal and Ovarian Cancers Tissues : a Pilot Study (clinicaltrials.gov) - Jul 18, 2017
P=N/A, N=70, Completed, Sponsor: Ain Shams University
Trial primary completion date: Oct 2014 --> Dec 2014 Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Mar 2017